Annual EBITDA
-$19.15 M
+$24.51 M+56.14%
December 31, 2023
Summary
- As of February 7, 2025, XGN annual EBITDA is -$19.15 million, with the most recent change of +$24.51 million (+56.14%) on December 31, 2023.
- During the last 3 years, XGN annual EBITDA has fallen by -$5.50 million (-40.26%).
- XGN annual EBITDA is now -339.79% below its all-time high of -$4.36 million, reached on December 31, 2018.
Performance
XGN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$4.47 M
-$2.49 M-125.90%
September 30, 2024
Summary
- As of February 7, 2025, XGN quarterly EBITDA is -$4.47 million, with the most recent change of -$2.49 million (-125.90%) on September 30, 2024.
- Over the past year, XGN quarterly EBITDA has dropped by -$213.00 thousand (-5.01%).
- XGN quarterly EBITDA is now -1237.13% below its all-time high of -$334.00 thousand, reached on December 31, 2018.
Performance
XGN Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$13.26 M
-$213.00 K-1.63%
September 30, 2024
Summary
- As of February 7, 2025, XGN TTM EBITDA is -$13.26 million, with the most recent change of -$213.00 thousand (-1.63%) on September 30, 2024.
- Over the past year, XGN TTM EBITDA has increased by +$14.91 million (+52.93%).
- XGN TTM EBITDA is now -1453.04% below its all-time high of -$854.00 thousand, reached on September 30, 2018.
Performance
XGN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
XGN EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +56.1% | -5.0% | +52.9% |
| 3 y3 years | -40.3% | +28.6% | +32.9% |
| 5 y5 years | -339.8% | -26.8% | +2.1% |
XGN EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +56.1% | -125.9% | +67.5% | -1.6% | +69.6% |
| 5 y | 5-year | -141.5% | +56.1% | -125.9% | +67.5% | -67.2% | +69.6% |
| alltime | all time | -339.8% | +56.1% | -1237.1% | +67.5% | -1453.0% | +69.6% |
Exagen EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$4.47 M(+125.9%) | -$13.26 M(+1.6%) |
| Jun 2024 | - | -$1.98 M(-16.0%) | -$13.05 M(-13.1%) |
| Mar 2024 | - | -$2.35 M(-47.3%) | -$15.01 M(-21.6%) |
| Dec 2023 | -$19.15 M(-56.1%) | -$4.47 M(+5.0%) | -$19.15 M(-32.0%) |
| Sep 2023 | - | -$4.25 M(+8.1%) | -$28.18 M(-9.0%) |
| Jun 2023 | - | -$3.94 M(-39.4%) | -$30.96 M(-24.1%) |
| Mar 2023 | - | -$6.50 M(-51.8%) | -$40.77 M(-6.6%) |
| Dec 2022 | -$43.66 M(+89.0%) | -$13.49 M(+91.7%) | -$43.66 M(+20.9%) |
| Sep 2022 | - | -$7.04 M(-48.8%) | -$36.12 M(+2.2%) |
| Jun 2022 | - | -$13.74 M(+46.4%) | -$35.34 M(+30.3%) |
| Mar 2022 | - | -$9.39 M(+57.9%) | -$27.12 M(+17.4%) |
| Dec 2021 | -$23.10 M(+69.2%) | -$5.95 M(-4.9%) | -$23.10 M(+16.9%) |
| Sep 2021 | - | -$6.25 M(+13.1%) | -$19.76 M(+16.0%) |
| Jun 2021 | - | -$5.53 M(+2.8%) | -$17.03 M(+20.7%) |
| Mar 2021 | - | -$5.38 M(+106.2%) | -$14.11 M(+3.3%) |
| Dec 2020 | -$13.65 M | -$2.61 M(-26.0%) | -$13.65 M(+0.8%) |
| Sep 2020 | - | -$3.52 M(+35.4%) | -$13.55 M(+11.6%) |
| Jun 2020 | - | -$2.60 M(-47.2%) | -$12.14 M(+8.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | -$4.92 M(+96.9%) | -$11.23 M(+41.6%) |
| Dec 2019 | -$7.93 M(+82.1%) | -$2.50 M(+18.3%) | -$7.93 M(+37.6%) |
| Sep 2019 | - | -$2.12 M(+24.9%) | -$5.76 M(+28.0%) |
| Jun 2019 | - | -$1.69 M(+4.5%) | -$4.50 M(+60.3%) |
| Mar 2019 | - | -$1.62 M(+385.3%) | -$2.81 M(+136.4%) |
| Dec 2018 | -$4.36 M(-80.7%) | -$334.00 K(-60.9%) | -$1.19 M(+39.1%) |
| Sep 2018 | - | -$854.00 K(-36.6%) | -$854.00 K(-93.7%) |
| Dec 2017 | -$22.56 M(+66.5%) | - | - |
| Dec 2015 | -$13.55 M(+17.9%) | -$1.35 M(-24.2%) | -$13.55 M(-1.3%) |
| Sep 2015 | - | -$1.78 M(-78.7%) | -$13.73 M(-13.0%) |
| Jun 2015 | - | -$8.32 M(+295.8%) | -$15.77 M(+48.4%) |
| Mar 2015 | - | -$2.10 M(+38.1%) | -$10.63 M(-7.6%) |
| Dec 2014 | -$11.49 M(-4.7%) | -$1.52 M(-60.1%) | -$11.49 M(-27.9%) |
| Sep 2014 | - | -$3.82 M(+20.0%) | -$15.94 M(+13.4%) |
| Jun 2014 | - | -$3.18 M(+7.0%) | -$14.05 M(+29.3%) |
| Mar 2014 | - | -$2.97 M(-50.2%) | -$10.87 M(+37.6%) |
| Dec 2013 | -$12.06 M(+87.8%) | -$5.97 M(+209.0%) | -$7.90 M(+309.0%) |
| Sep 2013 | - | -$1.93 M | -$1.93 M |
| Dec 2012 | -$6.42 M | - | - |
FAQ
- What is Exagen annual EBITDA?
- What is the all time high annual EBITDA for Exagen?
- What is Exagen annual EBITDA year-on-year change?
- What is Exagen quarterly EBITDA?
- What is the all time high quarterly EBITDA for Exagen?
- What is Exagen quarterly EBITDA year-on-year change?
- What is Exagen TTM EBITDA?
- What is the all time high TTM EBITDA for Exagen?
- What is Exagen TTM EBITDA year-on-year change?
What is Exagen annual EBITDA?
The current annual EBITDA of XGN is -$19.15 M
What is the all time high annual EBITDA for Exagen?
Exagen all-time high annual EBITDA is -$4.36 M
What is Exagen annual EBITDA year-on-year change?
Over the past year, XGN annual EBITDA has changed by +$24.51 M (+56.14%)
What is Exagen quarterly EBITDA?
The current quarterly EBITDA of XGN is -$4.47 M
What is the all time high quarterly EBITDA for Exagen?
Exagen all-time high quarterly EBITDA is -$334.00 K
What is Exagen quarterly EBITDA year-on-year change?
Over the past year, XGN quarterly EBITDA has changed by -$213.00 K (-5.01%)
What is Exagen TTM EBITDA?
The current TTM EBITDA of XGN is -$13.26 M
What is the all time high TTM EBITDA for Exagen?
Exagen all-time high TTM EBITDA is -$854.00 K
What is Exagen TTM EBITDA year-on-year change?
Over the past year, XGN TTM EBITDA has changed by +$14.91 M (+52.93%)